Search results
Results from the WOW.Com Content Network
In 2018, Amneal Pharmaceuticals LLC merged with Impax Laboratories, Inc. to form Amneal Pharmaceuticals, Inc. Shares of newly public AMRX began trading on the NYSE on May 7, 2018. [9] Concurrent with the Impax merger, Amneal acquired Gemini Laboratories for $117 million, including Unithroid, Gemini's lead product for treating hypothyroidism. [10]
Impax Laboratories, Inc. (Impax) is a technology based specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and ...
There's no foolproof way to know the future for Impax Laboratories (NAS: IPXL) or any other company. However, certain clues may help you see potential stumbles before they happen -- and before ...
What: Shareholders of generic-drug maker Impax. Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're ...
Impax Laboratories Announces Reduction in Workforce HAYWARD, Calif.--(BUSINESS WIRE)-- Impax Laboratories, Inc. (NAS: IPXL) today announced a reduction in its workforce as a part of the Company's ...
Impax Laboratories will release its quarterly report in early November, and investors are bracing themselves for the pharmaceutical company to post a loss, reversing a year-ago profit. But even ...
Impax Laboratories Enters Into Development, Manufacturing and Commercialization Agreement with Perrigo HAYWARD, Calif.--(BUSINESS WIRE)-- Impax Laboratories, Inc. today announced that it will ...
Impax Laboratories (NAS: IPXL) reported earnings on Thursday. Here are the numbers you need to know. The 10-second takeawayFor the quarter ended June 30 (Q2), Impax Laboratories beat expectations ...